{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:36:07Z","timestamp":1792647367944,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>A Phase 1, double-blind, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK) and food effect of alpibectir administered as single and multiple oral doses in healthy volunteers (NCT04654143).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eighty participants were randomized. In single ascending dose (SAD), a total of six dose levels of alpibectir (0.5 to 40\u2005mg) were tested under fasted and fed (10\u2005mg) conditions as single daily doses in sequential cohorts. In multiple ascending dose (MAD), repeat doses (5 to 30\u2005mg) were administered once daily for 7\u2005days in three sequential cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No serious adverse event was reported. Thirteen participants across groups experienced a total of 13 mild or moderate treatment-emergent adverse events. Alpibectir showed rapid absorption after single dose (mean Tmax range of 0.88 to 1.53\u2005h). Food affected the PK of alpibectir, characterized by a slower absorption (mean Tmax 3.87\u2005h), a lower Cmax (\u221217.7%) and increased AUC0\u2013t (+19.6%) compared with the fasted condition. Following repeat dosing, dose proportionality was shown for both Cmax and AUC0\u2013tau. Accumulation of alpibectir was observed across all doses, with a more profound effect on AUC during a dosing interval (AUC0\u2013tau) compared with Cmax (1.8- and 1.3-fold on average), respectively. Steady state was considered to have been achieved by Day 7 of dosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Alpibectir was generally well tolerated, and no clinically relevant safety findings were identified in the participants treated during SAD or MAD. The PK is dose-proportional and affected by food.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae107","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:25:23Z","timestamp":1713972323000},"page":"1353-1361","source":"Crossref","is-referenced-by-count":12,"title":["First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug"],"prefix":"10.1093","volume":"79","author":[{"given":"Michel","family":"Pieren","sequence":"first","affiliation":[{"name":"BioVersys AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ab\u00e1igar Guti\u00e9rrez-Solana","sequence":"additional","affiliation":[{"name":"CTI Laboratory Services S.L. , Ibaizabal bidea, 702, 48160 Derio, Biscay , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Antonijoan Arb\u00f3s","sequence":"additional","affiliation":[{"name":"Institut de Recerca de l'HSCSP, IIB Sant Pau, Centre d'Investigaci\u00f3 de Medicaments (CIM) , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W","family":"Boyle","sequence":"additional","affiliation":[{"name":"GSK , Stevenage , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Davila","sequence":"additional","affiliation":[{"name":"BioVersys AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Davy","sequence":"additional","affiliation":[{"name":"GSK , Stevenage , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gitzinger","sequence":"additional","affiliation":[{"name":"BioVersys AG , Basel , Switzerland"},{"name":"BioVersys SAS , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Husband","sequence":"additional","affiliation":[{"name":"BioVersys SAS , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda S","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"GSK , Tres Cantos , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores Ochoa","family":"Mazarro","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Clinical Pharmacology Department, Facultad de Medicina, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid (UAM), Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Pefani","sequence":"additional","affiliation":[{"name":"GSK , Stevenage , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L","family":"Penman","sequence":"additional","affiliation":[{"name":"GSK , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modesto J","family":"Remui\u00f1\u00e1n","sequence":"additional","affiliation":[{"name":"GSK , Tres Cantos , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Vlasakakis","sequence":"additional","affiliation":[{"name":"GSK , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Vienna University Hospital, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E","family":"Dale","sequence":"additional","affiliation":[{"name":"BioVersys AG , Basel , Switzerland"},{"name":"BioVersys SAS , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2024060223520719100_dkae107-B1","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"2024060223520719100_dkae107-B2","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1016\/S1473-3099(20)30792-1","article-title":"Food for thought: addressing undernutrition to end tuberculosis","volume":"21","author":"Sinha","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024060223520719100_dkae107-B3","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024060223520719100_dkae107-B4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"2024060223520719100_dkae107-B5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.339.6116.130","article-title":"Approval of novel TB drug celebrated\u2014with restraint","volume":"339","author":"Cohen","year":"2013","journal-title":"Science"},{"key":"2024060223520719100_dkae107-B6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"2024060223520719100_dkae107-B7","author":"Eristavi"},{"key":"2024060223520719100_dkae107-B8","doi-asserted-by":"crossref","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline","volume":"9","author":"Andries","year":"2014","journal-title":"PLoS One"},{"key":"2024060223520719100_dkae107-B9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2024060223520719100_dkae107-B10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/cid\/ciz074","article-title":"Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment","volume":"69","author":"Polsfuss","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024060223520719100_dkae107-B11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkab505","article-title":"Delamanid or pretomanid? A solomonic judgement!","volume":"77","author":"Mudde","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024060223520719100_dkae107-B12","doi-asserted-by":"crossref","first-page":"28326","DOI":"10.1074\/jbc.M003744200","article-title":"Activation of the pro-drug ethionamide is regulated in mycobacteria","volume":"275","author":"Baulard","year":"2000","journal-title":"J Biol Chem"},{"key":"2024060223520719100_dkae107-B13","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","article-title":"Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis","volume":"97","author":"DeBarber","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024060223520719100_dkae107-B14"},{"key":"2024060223520719100_dkae107-B15","first-page":"85","article-title":"Handbook of anti-tuberculosis agents","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"2024060223520719100_dkae107-B16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.chembiol.2016.05.011","article-title":"Baeyer-Villiger monooxygenases EthA and MymA are required for activation of replicating and non-replicating Mycobacterium tuberculosis inhibitors","volume":"23","author":"Grant","year":"2016","journal-title":"Cell Chem Biol"},{"key":"2024060223520719100_dkae107-B17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1126\/science.aag1006","article-title":"Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420","volume":"355","author":"Blondiaux","year":"2017","journal-title":"Science"},{"key":"2024060223520719100_dkae107-B18","doi-asserted-by":"crossref","first-page":"eaaz6280","DOI":"10.1126\/scitranslmed.aaz6280","article-title":"The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis","volume":"14","author":"Flipo","year":"2022","journal-title":"Sci Transl Med"},{"key":"2024060223520719100_dkae107-B19","doi-asserted-by":"crossref","first-page":"104807","DOI":"10.1016\/j.idnow.2023.104807","article-title":"Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis","volume":"54","author":"Maitre","year":"2023","journal-title":"Infect Dis Now"},{"key":"2024060223520719100_dkae107-B20","author":"US Food and Drug Administration"},{"key":"2024060223520719100_dkae107-B21","author":"Teuscher"},{"key":"2024060223520719100_dkae107-B22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurol.2019.07.007","article-title":"Tuberculous meningitis: challenges in diagnosis and management","volume":"7-8","author":"M\u00e9cha\u00ef","year":"2019","journal-title":"Rev Neurol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/6\/1353\/58036499\/dkae107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/6\/1353\/58036499\/dkae107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T23:53:13Z","timestamp":1717372393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/6\/1353\/7657603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,24]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae107","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,24]]}}}